Diabetes News Archive
Measuring the quality of life and status of health is imperative in patients with diabetes.
The FDA just approved a new short-acting insulin drug, Admelog, for patients with either T1D or T2D.
Remission was linked to 46% patients in intensive weight management programs.
Semaglutide helps patients with diabetes reduce blood glucose levels and lower body weight.
Lifestyle and clinical factors could have been misinterpreted, linking antibiotics to risk of diabetes.
Sulfonylureas and thiazolidinediones adherence was stronger than metformin adherence.
Diabetic patients with chronic kidney disease starting treatment with metformin have a 36% decreased risk of death compared with those starting on a sulfonylurea, study finds.
Severe hypoglycemia is associated with coronary heart disease, cardiovascular mortality, and cancer mortality.
Chemicals that inhibit endocrine functions may be associated with contrasts in diabetes-linked racial and socioeconomic disparities.
The combined effects of high BMI and diabetes resulted in 5.6% of all incident cancers in 2012.
For patients with diabetes, there was a significant decrease in hospitalization rates for acute coronary syndrome, cardiac dysrhythmia, heart failure, and certain strokes.
Effect is larger in chronic heart failure patients with diabetes than CHF patients without diabetes.
But sulfonylureas still most common drugs initiated as second-line treatment.
But significant improvements in HbA1c testing and awareness seen, except in those aged 20 to 44.
Increased risk seen for both all-cause mortality, sudden cardiac death in young people with diabetes.
Findings among a large study of Norwegian children followed for 40-plus years.
From 1995 to 2015, the prevalence of hypertension and diabetes among patients starting hemodialysis increased from 67.9% to 87.6% and from 43.1% to 59.6%, respectively.
In any Diabetes Prevention Program treatment group, statin use tied to increased diabetes risk.
Incidence of end-stage renal disease has declined but affects substantial portion of long-term T1D patients.
27% of CV deaths in diabetes patients with atherosclerotic CVD are categorized as sudden death.
Individualized management should include education, glycemic management plans, target HbA1c.
Stratification of T2D by HbA1c shows U-shaped associations for first hospitalization and mortality.
Greater improvement in CHD risk factors for combined intervention versus either alone.
Phase 3 studies next to assess longer-term/clinical outcomes, safety.
Adding sulfonylurea or metformin to insulin decreases HbA1c about 1
Case report describes treatment of female patient who attempted suicide with metformin overdose.
Greater drop in HbA1c with DPP4i added to alpha glucosidase inhibitor, with no increase in weight.
Similar findings among individuals with diabetes able to achieve normoglycemia.
Primary aim of diagetes management is lowering blood glucose or glycated hemoglobin (HbA1c) concentrations.
Second-line treatment often initiated without evidence of recommended use of first-line treatment.
Instead, sensor is implanted below skin in patients with diabetes.
Study of Medicare patients shows overtreatment for diabetes is rarely deintensified.
The results demonstrated a tendency for a decrease in LDL-C level at 24 weeks in the ANA group, and improvement was mediated through the suppression of apoB-100 synthesis.
Administration of exenatide in patients with type 2 diabetes at a wide range of cardiovascular risk appeared not to cause an increase in their overall cardiovascular risk.
This synopsis focuses on recommendations from the 2017 Standards of Care about monitoring and pharmacologic approaches to glycemic management for type 1 diabetes.
The researchers found that, compared with placebo, diacerein reduced HbA1c by 0.35% in the intention-to-treat analysis and by 0.41% in the per-protocol analysis.
Among pregnant women with FIR at 25, 30, and 36 weeks, the ratio of soluble fms-like tyrosine kinase 1 to placental growth factor was significantly higher.
Frequent consumption of alcohol is associated with the lowest risk of diabetes.
After 11 pounds gained, the risk of diabetes went up 31%, hypertension 14%, and cardiovascular disease 8%.
Liraglutide-treated patients were 22% less likely than placebo recipients to experience a composite outcome of renal events.
The addition of V/S ratio to age, eGFR, BNP, antiplatelet agents, and HbA1c significantly improved classification performance for CVD.
Meta-analysis of studies conducted around the world found that men with diabetes have more than 3.5 times increased risk for erectile dysfunction.
The researchers found that women who experienced premature menopause were 3.7 times more likely to develop diabetes.
The cardiac biomarker data provide support for the beneficial cardiovascular effect of sodium glucose co-transporter 2 inhibitors in T2DM.
Diabetes patients pursuing lifestyle interventions had a significantly increased risk of frailty fracture compared to diabetes support and education intervention patients.
Diabetes was seventh leading cause of death in 2015 in United States, according to report.
Addition of CCTA-detected obstructive coronary artery disease to risk factors ups prediction of MACE.
The rates of overall symptomatic hypoglycemia for insulin degludec vs insulin glargine were 185.6 vs 265.4 episodes per 100 PYEs.
Patients who achieved SVR had a greater drop in HbA1c associated with antiviral treatment than those who sustained treatment failure.
Between 2002 and 2013, heart failure hospitalizations declined by 30.8% nationwide, and continue to drop.
Therapeutic inertia was seen in 18.1% of the 12,730 patients with HbA1c of ≥8% at baseline or during follow-up.
The researchers found that 57% of participants expressed interest in learning their secondary germline findings, while 29% and 14%, respectively, were equivocal or disinterested.
The researchers found that new-onset AF correlated with increased risk of heart failure in multivariable models.
Earlier treatment remained significantly correlated with lower in-hospital mortality in multivariate analysis.
In a real-world population, patients with diabetes with high rates of statin and aspirin treatment had the same risk of cardiovascular events.
What's important is that doctors and other health-care providers, as well as patients, don't just assume these differences are normal and inconsequential.
The researchers found no differences between the groups in how well their blood glucose levels were controlled or in their quality of life.
In 96.2% of the episodes, blood glucose levels returned to normal within 30 minutes.
The researchers found that the primary outcome of first occurrence of an adjudicated major cardiovascular event occurred in 8.5% and 9.3% of patients in the degludec and glargine groups, respectively.
Study findings suggest that the medication may offer renal protection.
The investigators found that patients taking SGLT2 inhibitors were approximately twice as likely to develop diabetic ketoacidosis than those taking DPP4 inhibitors.
The NMTT is a reliable insulin secretion test in patients with type 2 diabetes, except those in a hyperglycemic state.
Participants lost 0.3% of body weight for every additional program session attended and every 30 minutes of activity reported.
There was a net 20% steps/day increase in active vs. control arm participants.
Amputations of the toe and middle of the foot were the most common, but leg amputations below and above the knee also occurred.
NODAT occurred more frequently in the upper PCSK9 tertile vs the lowest two PCSK9 tertiles.
Finding could explain the association between obesity and diabetes and the development of kidney stones.
The incidence of NODAT was 33.8% among patients who switched to everolimus and 36.4% among those who stayed on calcineurin inhibitors.
In a study, diabetes in both the donor and recipient was associated with triple the risk of death at 5 years post-transplant compared with the absence of diabetes in both the donor and recipient.
The adjusted 5-year risk of insulin use following donation is 5 times higher among obese vs normal weight donors.
A short course of intensive lifestyle and drug therapy achieves on-treatment normoglycemia and promotes sustained weight loss.
The largest numbers of diet-related cardiometabolic deaths were related to high sodium, low nuts/seeds, high processed meats, low seafood omega-3 fats, low vegetables, low fruits, and high SSBs.
Among 187 metabolites identified in urine metabolic profiles, 3 metabolites were significantly higher in obese youth with T2D than in non-diabetic obese youth.
CSII produced a significantly greater reduction in HbA1c than multiple daily injections, and the treatment difference increased with baseline HbA1c .
Hyperglycemia from genetics increases the risk of coronary artery disease separately from type 2 diabetes and other CAD risk factors.
Isocaloric diets high in animal or plant protein allow similar improvements of metabolism and cardiovascular risk factors in T2DM patients.
These cardiovascular profiles during enteral nutrient exposure may have implications for postprandial hypotension.
The study found that many patients who had a hypoglycemic episode also had high increased odds of cardiovascular disease or death.
The 2017 Updates focus on pharmacologic approaches to glycemic treatment of type 2 diabetes.
Timing of intensification of OAD therapy led to greater reductions in HbA1c and lower risks of complications.
In short-term treatment duration, there was no increased risk of myocardial infarction stroke or heart failure using DPP-4i vs SU/TZD.
Patients who used the drug had a 38% lower risk of dying from kidney cancer than non-users, meta-analysis shows.
Patients with diabetes had higher cumulative rates of 1-year all-cause death, CVD death, and HF hospitalization.
Patients who underwent surgical procedures had a greater mean percentage reduction from baseline in glycated hemoglobin level than did patients who received medical therapy alone.
The largest difference between adolescents with type 2 diabetes vs type 1 diabetes was obesity.
Among the etiologies of readmission, cardiac causes including heart failure and coronary artery disease were most common.
Statistically significant increases in BP, MAP, and serum lipid levels were observed with LY2409021 treatment at a dose that lowered HbA1c and glucose levels.
Participants with high TG and low HDL levels had a 1.32-fold greater HR for CHD than those with normal TG and normal HDL levels.
Swedish smokeless tobacco (snus) increases insulin resistance and the risk of type 2 diabetes.
Dapagliflozin was associated with lower risk of both all-cause mortality and CVD, whereas DPP-4i was only associated with lower risk of all-cause mortality.
Important concepts of obesity prevention and treatment were poorly represented.
Combination therapy was effective in lowering the HbA1c independent of sex, ethnicity, BMI, or baseline HbA1c.
An estimated 12.3% of Americans over the age of 21 have masked hypertension.
A small set of serum protein biomarkers combined with clinical variables, enhances the prediction of renal function loss over a wide range of baseline eGFR values.
Sitagliptin did not significantly impact the primary composite, death, heart failure hospitalization, severe hypoglycemia, rates of acute pancreatitis and pancreatic cancer, or serious adverse events.
Serum levels of 7 modified metabolites were associated with renal function decline and time to ESRD.
The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes.
To receive top ratings, a diet has to be relatively easy to follow, nutritious, safe, effective for weight loss, and protective against diabetes and heart disease.
Patients with type 2 diabetes had higher prevalence of CHB than the controls in the overall population.
The Indian Health Service has made progress by applying population health and team-based approaches to diabetes and kidney care.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)